Appeal No. 1997-2188
Application 08/137,440
treatment of Alzheimer's disease, the only disease mentioned
in their specification as including as a symptom thereof
memory loss due to decreased cholinergic function. The
examiner explains that appellants have failed to present
adequately reliable information in their disclosure for
effectively treating Alzheimer's disease. Specifically, the
examiner questions the reliability of appellants' screening
method for screening prospective drug candidates for treatment
of memory dysfunction characterized by decreased cholinergic
function. The examiner also questions whether appellants use
of the Dark Avoidance Test can reliably predict efficacy in2
humans of the claimed compounds.
At page 2 of his Answer, the examiner has listed various
prior art references which serve as the evidence which
supports his rejection. Of all the listed prior art the
examiner has proffered as evidence in support of his
rejection, we find the article by Han et al. in the European
Journal of Medical Chemistry to be the most relevant reference
to the issues presented for our determination. Han et al.
See page 7, line 23 through page 8, line 13 of the2
specification for an explanation of the Dark Avoidance
Test.
12
Page: Previous 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Next
Last modified: November 3, 2007